Tirzepatide associated with fewer asthma flare-ups in adults with obesity

A research letter published February 18, 2026, in Clinical & Experimental Allergy reports that adults with obesity who took tirzepatide had asthma exacerbations at a lower rate than matched adults who did not use the drug ^[1]. The retrospective cohort study found exacerbations occurred in 3.0 percent of tirzepatide users compared with 3.8 percent of non-users, and patients who did have flare-ups experienced fewer events per person ^[1].

Tirzepatide is sold as Mounjaro for type 2 diabetes and Zepbound for weight management. Unlike semaglutide (Ozempic, Wegovy, Rybelsus), which acts on one gut hormone receptor, tirzepatide activates two: the GLP-1 receptor and the GIP receptor ^[1]. Researchers have proposed that this dual action might calm airway inflammation more than GLP-1 drugs alone, citing earlier lab studies in mice showing that GLP-1 receptor activity reduced allergic airway inflammation and suppressed inflammatory pathways linked to asthma in obese animal models ^[1].

But a separate study, published later in 2026 in the Journal of Asthma and Allergy, complicates that idea. That paper compared tirzepatide directly against semaglutide, rather than against non-users, in patients who had both asthma and type 2 diabetes ^[2]. Using the same TriNetX health records network, researchers matched 8,176 patients in each treatment group and followed them for 12 months ^[2]. The risk of a first asthma exacerbation was nearly identical: 11.0 percent with tirzepatide versus 11.1 percent with semaglutide, a difference the study's statistical model treated as no real difference (hazard ratio 1.00, 95% confidence interval 0.91 to 1.10) ^[2].

The second study did find one secondary difference. Tirzepatide was linked to a lower risk of using short-acting rescue inhalers, sometimes called SABAs, than semaglutide (hazard ratio 0.92, 95% confidence interval 0.88 to 0.96) ^[2]. But there was no difference in how often patients needed systemic corticosteroids, a marker of more serious flare-ups (hazard ratio 1.01, 95% confidence interval 0.96 to 1.05) ^[2]. The authors concluded that among patients with both asthma and type 2 diabetes, there was no difference in exacerbation risk between the two drugs, and they called for randomized controlled trials to clarify any role for these medicines in asthma care ^[2].

Why it matters for patients

Asthma and obesity often occur together, and obesity can make asthma harder to control ^[1]. That has led researchers to ask whether weight-loss drugs might also ease breathing problems as a side benefit. The first study's finding, that tirzepatide users had fewer flare-ups than non-users, fit that hope ^[1]. But the second study shows that when tirzepatide is compared against another GLP-1 drug rather than against no treatment, the apparent respiratory edge mostly disappears for the main outcome of exacerbations ^[2]. This suggests any benefit may come from broader effects common to GLP-1 drugs generally, such as weight loss or reduced inflammation, rather than something unique to tirzepatide's dual mechanism. Patients taking either drug for diabetes or obesity should not expect a proven asthma benefit as a reason to switch medications based on current evidence, since neither study was a randomized trial designed to test that question directly, and both relied on retrospective health records rather than controlled experiments ^[1][2].

What happens next

Both research teams note that further study is needed. The Journal of Asthma and Allergy study explicitly called for randomized controlled trials to test whether GLP-1 receptor agonist-based therapies affect asthma outcomes in people with type 2 diabetes ^[2]. No timeline for such trials was given in either source. Until then, the question of whether tirzepatide, semaglutide, or GLP-1 drugs as a class meaningfully reduce asthma exacerbations beyond their effects on weight and blood sugar remains unresolved ^[1][2].